Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Medical Technology
  • Newly formed Jaguar acquires Afib device assets from J&J

Newly formed Jaguar acquires Afib device assets from J&J

September 15, 2026Posted inMedical Technology

Jaguar LAA, a newly formed medtech, has acquired assets that are part of Johnson & Johnson’s AFib device Laminar program for an undisclosed price.

Post navigation

Previous Post
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
Next Post
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech

Recent Posts

  • Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s
  • Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles
  • Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies
  • Consolidating Antibody Discovery Data with an AI Platform
  • FDA launches pilot program to speed up sluggish phase 1 trials

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top